Posted on February 25, 2008 by jrowley
Q Therapeutics, a cell therapy company focusing on neural applications, recently announced a $15M series B financing that included funding from multiple venture capital (VC) groups as well as biotech tools provider Invitrogen. Q’s lead product, Q-Cells™, is an allogeneic product intended to restore function to damaged neurons by providing trophic (e.g. cytokines, growth [...]
Filed under: Bioprocessing, Clinical Trials, Company Profiles, MS, Manufacturing, Neural Repair, Q Therapeutics, Regenerative Medicine, adult stem cell, stem cells | Tagged: symbiotic business relationships, cell therapy tools, cell therapy development, GMP-grade kits and reagents | 2 Comments »
Posted on February 24, 2008 by shsiong
by Susan Hsiong, PhD
More than 12 million minimally invasive vascular surgeries are done every year. These [...]
Filed under: AccessClosure, Biomaterials, Datascope, NeoMend, PEG-based Biomaterials, St. Jude Medical, Vascular Closure, biomaterial devices, vascular regeneration | Tagged: AccessClosure, biomaterial devices, catheterization, endovascular, Mynx, NeoMend, ProGEL, vascular closure devices | No Comments »
Posted on February 14, 2008 by jrowley
ES cell biopsy from blastocyst.
Filed under: Advanced Cell Technology, Athersys, Clinical Trials, Cytori, Embyonic Stem Cells, FDA, Geron, JNJ, Novocell, Osiris, Regenerative Medicine, adult stem cell, spinal cord injury, stem cells | Tagged: Clinical Trials, embryonic vs adult stem cell, embyryonic stem cell 2008, evolving clinical landscape, safety issues | No Comments »
Posted on February 7, 2008 by jrowley
Geron yesterday announced the issuance of US patent #7,326,572, helping to extend their patent protection around their embryonic stem (ES) cell platform technology in the area of treating type 1 diabetes. Currently, Geron owns an exclusive license from the Wisconsin Alumni Research Foundation (WARF) for James Tomson’s original ES patents. This license allows [...]
Filed under: Embyonic Stem Cells, Geron, Intellectual Property, Novocell, Regenerative Medicine, Type 1 diabetes | Tagged: culture conditions, embryonic germ cells, endoderm, patent protection | No Comments »
Posted on February 5, 2008 by jrowley
I always found it extremely useful to read and monitor job posts, even well before I had any reason to send out my resume. Reading about various jobs give you an understanding of 1) what jobs are out there that you might be interested in, and more importantly 2) what gaps you have in [...]
Filed under: Job search, Regenerative Medicine | Tagged: career development, job posts, skills for the next job | No Comments »
Posted on February 1, 2008 by jrowley
Cytori Therapeutics announced that they have enrolled their first two patients in an acute myocardial infarction clinical trial using adipose-derived cells prepared using their Celution™ device. The Celution™ device is an automated, tissue processing unit that isolates cells from adipose tissue derived via liposuction.
Filed under: Bioprocessing, Clinical Trials, Company Profiles, Cytori, Device-centric cell therapies, Regenerative Medicine, adult stem cell, autologous, cardiac regeneration, cell delivery, patient specific cell therapy, personalized medicine, stem cells | No Comments »
